RTTNews | Jun 28, 2021 10:08AM EDT

10:08 Monday, June 28, 2021 (RTTNews.com) - Shares of Intellia Therapeutics Inc. (NTLA) are surging nearly 50% on Monday morning driven by positive results from an ongoing early-stage study of its Crispr/CA9-based treatment for transthyretin amyloidosis, a protein-based disorder that often leads to heart failure.

NTLA is currently trading at $132.77, up $43.94 or 49.47%, on the Nasdaq. The stock has traded between $16.54 and $144.40 in the 52 week period. The stock's value has almost quadrupled in that period.

NTLA-2001 represents the first-ever in vivo CRISPR treatment delivered intravenously to a patient. It is a part of a co-development/co-promotion agreement between Intellia and Regeneron Pharmaceuticals Inc. (REGN).

Transthyretin amyloidosis, or ATTR, is a rare, progressive and fatal disease. Hereditary ATTR (hATTR) occurs when a person is born with DNA mutations in the TTR gene, which causes the liver to produce a protein called transthyretin (TTR) in a misfolded form and build up in the body.

The interim readout, which covers the first 6 patients, from the ongoing Phase 1 trial, reveals that a single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, i.e., the disease-causing protein, with a maximum 96% serum TTR reduction by day 28, with dose-dependent response.

Read the original article on RTTNews ( https://www.rttnews.com/3205454/intellia-up-50-on-promising-results-from-crispr-therapy-based-transthyretin-amyloidosis-treatment.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved